Teprotumumab: a disease modifying treatment for graves' orbitopathy.

ABSTRACT:

Background

On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves' orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled clinical trials.

Discussion

This article discusses the outcomes of those trials and the potential role of teprotumumab in altering current treatment paradigms in Graves' orbitopathy. Future challenges are explored, including the need to confirm its disease-modifying effect, to establish its optimal position in the treatment pathway, and to define the appropriate subset of patients who would benefit from its use.

Conclusions

The results from these two large clinical trials have shown teprotumumab to have remarkable effect

SUBMITTER: Ting M 

PROVIDER: S-EPMC7334856 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature